StEpi: Steps for Epilepsy

Sponsor
Wake Forest University Health Sciences (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05359003
Collaborator
(none)
30
1
2
19
1.6

Study Details

Study Description

Brief Summary

The purpose of this research study is to evaluate the feasibility of a 12-week, telehealth delivered, step-goal based physical activity intervention in people with epilepsy. The study team will also evaluate the physical activity profiles of people with epilepsy both at rest and when engaged in physical activity and gather information on the effect of the intervention on epilepsy and epilepsy associated comorbidities.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: 12-week physical activity program
N/A

Detailed Description

This is a randomized, controlled, pilot trial to assess the feasibility of a 12-week telehealth delivered, step-goal based physical activity intervention in people with epilepsy. This will be carried out using a 2-arm, parallel group design with a wait list attention control. Participants will undergo formal exercise testing to establish a baseline fitness level and safety of participation. They will wear Garmin activity tracker on their wrist throughout the study to track their steps. During a 4 week baseline period, we will gather data on baseline physical activity levels and seizure frequency. Participants will then be randomized to either the intervention group of a wait-list control group. The intervention group will undergo a 12-week, telehealth delivered, step goal based physical activity intervention with a goal of ultimately achieving at least 8,000 steps per day. The intervention will utilize social cognitive theory to encourage lasting behavior changes and have weekly group coaching sessions with a trained health and behavior change provider. The control group will receive education every two weeks but will not be given a coaching plan. At the end of the intervention period, the control group will have the option to participate in the intervention while the intervention group will be evaluated for another 12 weeks to assess sustainability. The study will evaluate adherence to the intervention after the formal coaching program ends, and acceptability of the intervention. The study will also investigate the physical activity profile of people with epilepsy both at rest and when asked to participate in physical activity with a self-selected intensity and bout duration. the study will collect information on the effect of the intervention on seizures, mood, quality of life, sleep, fitness, and heart-rate variability, as well as other epilepsy relevant outcomes.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
A randomized, controlled trial with a two-arm, parallel group design with a wait-list educationA randomized, controlled trial with a two-arm, parallel group design with a wait-list education
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
A Feasibility Study of a Step-goal Based Physical Activity Intervention in People With Epilepsy
Anticipated Study Start Date :
Nov 1, 2022
Anticipated Primary Completion Date :
Jun 1, 2024
Anticipated Study Completion Date :
Jun 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Arm 1: Exercise Intervention

Participants in this arm will undergo a 12-week physical activity program aimed to achieve the equivalent of 8,000 steps per day (56,000 weekly steps).

Behavioral: 12-week physical activity program
Program aimed to achieve the equivalent of 8,000 steps per day (56,000 weekly steps). Includes weekly meetings with a trained health coach.

No Intervention: Arm 2 Control

Participants randomized to the wait-list attention control group will continue to undergo standard care for 12 weeks.

Outcome Measures

Primary Outcome Measures

  1. Proportion of participants who achieve their assigned step goal - adherence [Week 12 to Week 14]

    As measured by average daily steps via the Garmin device over the last 4 weeks of the intervention period.

  2. Proportion of participants who achieve their assigned step goal- sustainability [Week 24 to Week 28]

    As measured by average daily steps via the Garmin device over the last 4 weeks of the intervention period, will be calculated and 95% binomial confidence intervals generated.

Secondary Outcome Measures

  1. Time spent sedentary [Week 4, Week 16, and Week 28]

  2. Time spent in light intensity activity [Week 4, Week 16, and Week 28]

  3. Time spent in moderate intensity activity [Week 4, Week 16, and Week 28]

  4. Time spent in vigorous intensity activity [Week 4, Week 16, and Week 28]

  5. Exit survey [Week 28]

    The scale ranges from 4-20 with higher scores indicating greater satisfaction with the study.

  6. Exercise Satisfaction Survey- Proportion of participants with a 4 or higher response [Week 16]

    We will use the question "How satisfied were you with the exercise intervention?" with scale of 1-5, 1=VERY UNSATISFIED, 2=UNSATISFIED, 3=NEUTRAL, 4=SATISFIED, 5=VERY SATISFIED. Higher numbers denotes better outcomes. We will calculate the proportion of subjects who answer 4 or above.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age 18 or older

  • Focal or generalized epilepsy, as determined clinically by a WFBH epileptologist with no significant consideration of an alternative diagnosis

  • Access to a smartphone with application capabilities

  • Internet access or cellular data plan to attend virtual sessions

  • Able to ambulate independently

Exclusion Criteria:
  • Diagnosis of nonepileptic or psychogenic spells

  • Seizures associated with falls with injury (such as atonic seizures)

  • Medical conditions that would limit ability to participate in an exercise intervention including:

Stage III or IV Congestive Heart Failure (CHF) End-stage Renal Disease Severe dementia or significant cognitive impairment that precludes participation in the intervention or limits ability to follow the study protocol Uncontrolled hypertension (HTN) defined as systolic blood pressure greater than 180 mmHg and diastolic blood pressure greater than 110 mmHg at rest Severe arthritis, amputations, or orthopedic problems that limit ambulatory ability

  • Currently pregnant or plan to become pregnant during the study period (16 weeks)

  • Current use of beta-blockers

  • An active Central Nervous System (CNS) infection, demyelinating disease, degenerative neurologic disease or any CNS disease deemed to be progressive during the course of the study that may confound the interpretation of the study results

  • Any clinically significant psychiatric illness, psychological, or behavioral problems that would interfere with the subject's ability to participate in the study.

  • Unwilling or unable to comply with all study visits and procedures

  • Participants who have <75% complete days of seizure recording in the study diary or step data via the Garmin device will not be randomized.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Atrium Health Wake Forest Baptist Winston-Salem North Carolina United States 27046

Sponsors and Collaborators

  • Wake Forest University Health Sciences

Investigators

  • Principal Investigator: Halley Alexander, MD, Wake Forest Health Sciences

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Wake Forest University Health Sciences
ClinicalTrials.gov Identifier:
NCT05359003
Other Study ID Numbers:
  • IRB00084252
First Posted:
May 3, 2022
Last Update Posted:
May 3, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Wake Forest University Health Sciences
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 3, 2022